AbbVie, a research-based global biopharmaceutical company, has announced it will present data from clinical trials across multiple blood cancers evaluating venetoclax, a first-in-class oral B-cell lymphoma-2 (BCL-2) inhibitor, as monotherapy and in combination with other therapies at the 23rd European Hematology Association (EHA) Annual Congress, in Stockholm, Sweden. A total of 11 abstracts will be presented, including results of venetoclax in chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), multiple myeloma (MM) and acute lymphoblastic leukemia (ALL).
Studies of venetoclax in CLL and AML have been chosen for oral presentations, including an undetectable minimal residual disease (uMRD) sub-analysis from the pivotal Phase 3 MURANO study of venetoclax in combination with rituximab in patients with relapsed/refractory (R/R) CLL. Minimal residual disease is an objective measure of disease defined by the presence of less than one CLL cell in 10,000 white blood cells remaining in the blood or bone marrow following treatment. Prospective clinical trials have suggested that achieving undetectable minimal residual disease, may have a prognostic impact on clinical outcomes.
Neil Gallagher, M.D., Ph.D., head of oncology clinical development, AbbVie said, “The breadth of venetoclax studies being presented at the European Hematology Association Annual Congress, across four blood cancers, is an indicator of the utility, versatility and potential to advance care for patients living with blood cancer around the world.”